miRNA-600在急性髓系白血病中的表达及意义

Expression and significance of mi RNA-600 in acute myeloid leukemia

目的探讨微小核糖核酸-600(miRNA-600,miR-600)在急性髓系白血病(AML)中的表达及意义。方法选取池州市人民医院血液科2010年1月至2018年6月收治并明确为AML的患者80例作为AML组,采集同期非恶性血液病患者标本25例作为对照组,用qRT-PCR检测两组骨髓标本中miR-600表达水平,进行随访,分析miR-600表达水平与临床特征及预后的关系。结果 AML组miR-600相对表达量低于对照组(P <0. 01)。以m R-600相对表达水平的截断值0. 0054作为分界,将80例AML患者分为低表达组(33例)和高表达组(47例)。miR-600低表达患者WBC计数高于高表达患者(P=0. 021),Fms样酪氨酸激酶3 (FLT3)/内部串联重复(ITD)突变发生率明显高于miR-600高表达患者(P=0. 044),其他临床特征和基因突变类型两组间无差异(P均> 0. 05)。对70例非M3型AML患者进行随访,miR-600低表达组的完全缓解率稍低于miR-600高表达组,但差异无统计学意义(P=0. 112);总生存期(中位生存期7个月)明显低于miR-600高表达组(中位生存期13个月)(P=0. 019)。多变量分析发现,在非M3 AML患者中,miR-600低表达(P=0. 006)、高龄(P=0. 012)和FLT3/ITD突变(P=0. 003)是不良预后的独立影响因素。结论 miR-600在AML患者中表达水平低于对照组,并且与不良的临床结果有关。

Objective To investigate the expression of micro RNA-600( miR-600) in acute myeloid leukemia( AML) and its significance. Methods Eighty patients with AML confirmed and treated from January 2010 to June 2018 were selected as AML group,and 25 patients with non-malignant hematological diseases at the same period were served as control group. Using q RT-PCR,the expression level of miR-600 in bone marrow samples of two groups was detected,and the associations of miR-600 expression level with clinical characteristics and prognosis were analyzed in AML patients. Results The relative expression level of miR-600 in AML group was statistically lower than that in control group( P < 0. 01). As the cut-off value of miR-600 expression level was 0. 0054,80 AML patients were divided into low expression group( n =33) and high expression group( n = 47). WBC count and the incidence of FLT3/ITD mutation in low expression group were significantly higher than those in high expression group( P = 0. 021,P = 0. 044). There were no statistical differences in other clinical features and gene mutation types between two groups( all P > 0. 05). Follow-up for 70 patients with non-M3 AML showed that the complete remission( CR) rate in low-expression group was slightly lower than that in high-expression group( P = 0. 112),and the overall survival( OS) time( median OS,7 months vs 13 months,P = 0. 019) in low-expression group was significantly lower than that in high expression group. Multivariate analysis showed that in non-M3 AML patients,low expression of miR-600( P = 0. 006),old age( P = 0. 012) and FLT3/ITD mutation( P = 0. 003) were the independent influencing factors of poor prognosis. Conclusion The expression level of miR-600 in AML patients is lower than that in control group,and is related to poor clinical outcomes.